Treatment for chronic methicillin-sensitive<i>Staphylococcus aureus</i>pulmonary infection in people with cystic fibrosis

Ahmed, Molla Imaduddin; Mukherjee, Saptarshi

doi:10.1002/14651858.cd011581.pub3

Cited by 9 publications

(8 citation statements)

References 69 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, both compounds 1 and 5 affected S. aureus, for which connection with lung diseases is also postulated, since it causes serious pulmonary infections in adults with concomitant illnesses that are typically nosocomial or in patients with cystic fibrosis. 33 Human isolates, such as the strain S. aureus h, are well known to be more resistant to common antibiotics due to general phenomena of antibiotic resistance that is accelerated by the misuse or overuse of antibiotics, as well as poor infection prevention and control. 34 Hence, the modest effect obtained for both compounds 1 and 5 on tested human strains could implicate these ILs as new pharmacons with antimicrobial potential.…”

Section: Resultsmentioning

confidence: 99%

Anticancer and antimicrobial properties of imidazolium based ionic liquids with salicylate anion

et al. 2020

View full text Add to dashboard Cite

Ionic liquids (ILs) are well known for their physicochemical properties that recommend them for many purposes. However, many ILs are not environmentally friendly. Bearing these facts in mind, a series of imidazoliumand salicylate-based ILs with low general toxicity were designed and their pharmacological potential studied. Herein, their antiproliferative effect against human cancer cell lines and antimicrobial activity on selected Gram-positive and Gram-negative bacteria and Candida strains are presented. ILs with 1-butyl--3-methylimidazolium or imidazolium cation (IL 1 and compound 5), with the lowest dipole moments and highest lipophilicity, exerted highest cytotoxicity against colon and/or lung cancer cells, manifesting high selectivity to the normal cells. The most non-polar IL with the 1-butyl-3-methylimidazolium cation expressed the strongest anticancer potential, but it was also toxic against normal cells, although its cytotoxicity was less than the cytotoxic effect of commercially used chemotherapeutic agents. The same compounds, IL 1 and compound 5, expressed modest effect on the bacterial strain that causes serious lung diseases and pulmonary infections (Staphylococcus aureus) or which are included in colon cancer formation (Esherichia coli and Enterococcus faecalis). Salicylate itself was toxic against lung cancer cell line A549 and affected some Candida strains.

show abstract

Section: Resultsmentioning

confidence: 99%

Anticancer and antimicrobial properties of imidazolium based ionic liquids with salicylate anion

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Unlike P . aeruginosa strategies, where there is universal consensus regarding the approach [ 15 ], there is no agreement regarding MSSA infection [ 39 ]. Furthermore, the follow-up period of the present study did not allow us to ascertain whether the MSSA increase was transitory or persistent.…”

Section: Discussionmentioning

confidence: 99%

Methicillin-resistant Staphylococcus aureus eradication in cystic fibrosis patients: A randomized multicenter study

et al. 2019

View full text Add to dashboard Cite

BackgroundFew studies, based on a limited number of patients using non-uniform therapeutic protocols, have analyzed Methicillin-resistant Staphylococcus aureus (MRSA) eradication.MethodsIn a randomized multicenter trial conducted on patients with new-onset MRSA infection we evaluated the efficacy of an early eradication treatment (arm A) compared with an observational group (B). Arm A received oral rifampicin and trimethoprim/sulfamethoxazole (21 days). Patients’ microbiological status, FEV1, BMI, pulmonary exacerbations and use of antibiotics were assessed.ResultsSixty-one patients were randomized. Twenty-nine (47.5%) patients were assigned to active arm A and 32 (52.5%) patients to observational arm B. Twenty-nine (47.5%) patients, 10 patients in arm A and 19 in arm B, dropped out of the study. At 6 months MRSA was eradicated in 12 (63.2%) out of 19 patients in arm A while spontaneous clearance was observed in 5 (38.5%) out of 13 patients in arm B. A per-protocol analysis showed a 24.7% difference in the proportion of MRSA clearance between the two groups (z = 1.37, P(Z>z) = 0.08). Twenty-seven patients, 15 (78.9%) out of 19 in arm A and 12 (92.3%) out of 13 in arm B, were able to perform spirometry. The mean (±SD) FEV1 change from baseline was 7.13% (±14.92) in arm A and -1.16% (±5.25) in arm B (p = 0.08). In the same period the BMI change (mean ±SD) from baseline was 0.54 (±1.33) kg/m2 in arm A and -0.38 (±1.56) kg/m2 in arm B (p = 0.08). At 6 months no statistically significant differences regarding the number of pulmonary exacerbations, days spent in hospital and use of antibiotics were observed between the two arms.ConclusionsAlthough the statistical power of the study is limited, we found a 24.7% higher clearance of MRSA in the active arm than in the observational arm at 6 months. Patients in the active arm A also had favorable FEV1 and BMI tendencies.

show abstract

“…In Europe, the prevalence of MRSA is below 10% in most countries, while the prevalence of MSSA is also high, except in the UK, where continuous antistaphylococcal treatment is part of the regular therapy regimen from the beginning of In 2018, the prevalence of Methicillin-resistant S. aureus (MRSA) and Methicillin-sensitive S. aureus (MSSA) in individuals with CF in the United States was 25% and 55.3%, respectively [3,9]. In Europe, the prevalence of MRSA is below 10% in most countries, while the prevalence of MSSA is also high, except in the UK, where continuous anti-staphylococcal treatment is part of the regular therapy regimen from the beginning of diagnosis [10]. Patients infected by MRSA are characterized by worse lung function, higher mortality, and increased hospitalization, and therefore MRSA pose a particular threat to CF patients, while there is so far no consensus on optimal treatment strategies for either MRSA or for MSSA [11][12][13][14].…”

Section: Pathogenesis Of S Aureus With Respect To Cystic Fibrosismentioning

confidence: 99%

Staphylococcus aureus and Cystic Fibrosis—A Close Relationship. What Can We Learn from Sequencing Studies?

et al. 2021

View full text Add to dashboard Cite

Staphylococcus aureus is next to Pseudomonas aeruginosa the most isolated pathogen from the airways of cystic fibrosis (CF) patients, who are often infected by a dominant S. aureus clone for extended periods. To be able to persist, the pathogen has to adapt to the hostile niche of the airways to counteract host defence, antibiotic therapy and the competition with coinfecting pathogens. S. aureus is equipped with many virulence factors including adhesins, toxins that are localized on the chromosome, on plasmids or are phage-related. S. aureus is especially versatile and adaptation and evolution of the pathogen occurs by the acquisition of new genes by horizontal gene transfer (HGT), changes in nucleotides (single nucleotide variations, SNVs) that can cause a selective advantage for the bacteria and become fixed in subpopulations. Methicillin-resistant S. aureus are a special threat to CF patients due to the more severe lung disease occurring in infected patients. Today, with decreasing costs for sequencing, more and more studies using S. aureus isolates cultured from CF patients are being published, which use whole genome sequencing (WGS), multilocus sequence typing (MLST) or spa-sequence typing (spa-typing) to follow the population dynamics of S. aureus, elucidate the underlying mechanisms of phenotypic variants, newly acquired resistance or adaptation to the host response in this particular niche. In the first part of this review, an introduction to the genetic make-up and the pathogenesis of S. aureus with respect to CF is provided. The second part presents an overview of recent studies and their findings using genotypic methods such as single or multilocus sequencing and whole genome sequencing, which identify factors contributing to the adaptation of S. aureus and its evolution in the airways of individuals with CF.

show abstract

Treatment for chronic methicillin-sensitiveStaphylococcus aureuspulmonary infection in people with cystic fibrosis

Abstract: Treatment for chronic methicillin-sensitive Staphylococcus aureus pulmonary infection in people with cystic fibrosis.

Cited by 9 publications

References 69 publications

Anticancer and antimicrobial properties of imidazolium based ionic liquids with salicylate anion

Anticancer and antimicrobial properties of imidazolium based ionic liquids with salicylate anion

Methicillin-resistant Staphylococcus aureus eradication in cystic fibrosis patients: A randomized multicenter study

Staphylococcus aureus and Cystic Fibrosis—A Close Relationship. What Can We Learn from Sequencing Studies?

Contact Info

Product

Resources

About